Evidence map›Paper›PMID 30151671›Full record

ArticleVirchows Archiv : an international journal of pathology2018

Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type.

Giuseppe Lo Bello, Ayse U Akarca, Maria Raffaella Ambrosio, Claudio Agostinelli, Hernan Molina-Kirsch, Alan Ramsay, Manuel Rodriguez-Justo, Matt Pugh, Shuchun Zhao, Monique DeLisser and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 4 countries.

Giuseppe Lo BelloDepartment of Medical Biotechnologies, Section of Pathology, University of Siena, 53100, Siena, Italy.
Ayse U AkarcaDepartment of Histopathology, University College London, University College Hospital, Rockefeller Building, UCL Site, 21 University Street, London, WC1E 6JJ, UK.
Maria Raffaella AmbrosioDepartment of Medical Biotechnologies, Section of Pathology, University of Siena, 53100, Siena, Italy.
Claudio AgostinelliHaematopathology Unit, Department of Experimental Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, 40138, Bologna, Italy.
Hernan Molina-KirschDepartment of Pathology, San Juan General Hospital, 10303, Guatemala City, Guatemala.
Alan RamsayDepartment of Cellular Pathology, University College Hospital London, London, WC1E 6JJ, UK.
Manuel Rodriguez-JustoDepartment of Cellular Pathology, University College Hospital London, London, WC1E 6JJ, UK.
Matt PughDepartment of Pathology, University Hospital of Wales, Cardiff, CF14 4XW, UK.
Shuchun ZhaoDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, 94305-5324, USA.
Monique DeLisserDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, 94305-5324, USA.
Elena SabattiniHaematopathology Unit, Department of Experimental Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, 40138, Bologna, Italy.
Stefan DojcinovDepartment of Pathology, University Hospital of Wales, Cardiff, CF14 4XW, UK.
Stefano A PileriUniversity of Bologna, University School of Medicine, 40138, Bologna, Italy.
Yasodha NatkunamDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, 94305-5324, USA.
Lorenzo LeonciniDepartment of Medical Biotechnologies, Section of Pathology, University of Siena, 53100, Siena, Italy.
Teresa MarafiotiDepartment of Histopathology, University College London, University College Hospital, Rockefeller Building, UCL Site, 21 University Street, London, WC1E 6JJ, UK. t.marafioti@ucl.ac.uk.
Stanford University · USUniversity College London · GBUniversity of Siena · ITUniversity Hospital of Wales · GBUniversity of Bologna · ITHospital General San Juan de Dios · GTPoliclinico S.Orsola-Malpighi · ITUniversity College Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Granulysin is a cytolytic protein expressed in cytotoxic T and natural killer (NK) cells. Abnormal serum levels of granulysin in lymphomas with NK and cytotoxic phenotype have been shown to correlate with tumour progression. In this study, we investigated the expression pattern of granulysin in routine sections of normal and reactive lymphoid tissues as well as in a large series of lymphomas. In normal tissues, granulysin labelled a small population of cells that double immunostaining revealed to belong to the pool of cytotoxic T/NK cells. Among lymphoid neoplasms, the highest expression of granulysin (71%) was found in extranodal NK/T cell lymphomas of nasal type (ENKTL). To note is that 29% of ENKTLs, which were negative for one or more of classical cytotoxic markers strongly expressed granulysin. Furthermore, expression of granulysin was observed in rare cases of T cell lymphomas with a cytotoxic phenotype (i.e. ALK-negative anaplastic large cell lymphoma (26%), enteropathy-associated T cell lymphoma (12%) and peripheral T cell lymphoma, NOS (4%)). None of the investigated non-Hodgkin B cell lymphomas, Hodgkin lymphoma and plasma cell myeloma were granulysin positive. The results suggest granulysin as a novel marker for a subset of cytotoxic NK cell derived malignancies and its usefulness is highlighted in those ENKTLs that lack expression of other cytotoxic markers but retain granulysin expression.

Indexed as

AdolescentAdultAgedAged, 80 and overAntigens, Differentiation, T-LymphocyteBiomarkers, TumorChildFemaleHumansLymphoma, Extranodal NK-T-CellMaleMiddle AgedYoung AdultAntigens, Differentiation, T-LymphocyteBiomarkers, TumorGNLY protein, humanGranulysinImmunohistochemistryNK-T cellsPhenotypeT cell lymphoma

Identifiers

PMID30151671
PMCPMC6267266
OpenAlexW2889077258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.